UK patients could soon gain earlier access to breakthrough medical devices as clinical investigations in the country reach record levels in 2025. Data from the Medicines and Healthcare products Regulatory Agency (MHRA) show a 17 per cent rise in approved clinical investigations compared with last year, reflecting growing confidence in Great Britain as a testing ground for cutting-edge health technologies. The MHRA is also introducing measures to support innovation and reduce barriers for smaller companies, including a fee waiver pilot, early market access to promising devices, and enhanced support for high-impact technologies.
For patients, this growth promises earlier access to potentially life-changing treatments, while the NHS benefits from improved tools to diagnose disease, manage long-term conditions, and deliver more precise care. The increase in clinical investigations mirrors a global drive to tackle some of the most challenging health conditions. Neurotechnology is a particular focus, with studies targeting dementia, Parkinson’s disease, and epilepsy doubling since 2024 to account for roughly a quarter of all UK applications. Recent approvals include feasibility studies on deep brain stimulation for addiction disorders and first-in-human pediatric research testing rechargeable brain stimulation devices for children with severe epilepsy.
AI-powered medical devices are also seeing rapid growth, including tools that scan medical images for earlier disease detection, guide treatment decisions, and personalize patient care. New studies are exploring digital solutions that adjust treatment in real time, such as apps for managing chronic obstructive pulmonary disease, while advanced eye technologies are being tested to protect and restore vision. Collectively, these advances promise faster diagnosis, more precise treatment, and earlier patient access to innovative technologies.
Companies are drawn to the UK for speed, regulatory certainty, and expertise. The MHRA has met 100 per cent of statutory deadlines for clinical investigation applications since September 2023, with 2025 average approval times at 51 days—faster than the 60-day target. Researchers also benefit from hands-on scientific support and specialist advice, helping design safer and more robust studies.
To maintain this momentum, the MHRA is rolling out new measures to encourage innovation and support smaller companies. From January 2026, micro and small UK firms can benefit from a pilot fee waiver scheme to help bring high-potential ideas to market. The MHRA is also part of a UK-wide partnership led by Newcastle University to update national guidance on neurotechnology research, streamlining the process for clinicians, researchers, and companies working with devices that interact with the brain and nervous system.
MHRA Chief Executive Lawrence Tallon highlighted the UK’s standout year for medical device innovation, particularly in brain health, emphasizing the agency’s commitment to supporting the most promising ideas while ensuring patient safety. MHRA officials underscored that expanded specialist advice meetings and early engagement opportunities help turn promising concepts into real-world clinical investigations.
Industry leaders, including the Association of British HealthTech Industries, noted that the UK’s strong regulatory environment attracts investment and innovation, enabling faster development and delivery of HealthTech solutions. Clear and predictable regulation across devices, diagnostics, and digital products ensures that research activity translates into sustained growth and improved patient outcomes.
The combination of record growth in clinical investigations and the MHRA’s innovation-focused initiatives positions the UK as a global leader in medical technology and ensures patients gain faster access to the next generation of life-changing devices.
